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The production of recombinant biopharmaceuticals (pharmaceutical proteins) is a strongly
growing area in the pharmaceutical industry. While most products to date are produced
in mammalian cell cultures, namely Chinese hamster ovary cells, plant-based production
systems gained increasing acceptance over the last years. Different plant systems have
been established which are suitable for standardization and precise control of cultivation
conditions, thus meeting the criteria for pharmaceutical production. The majority of
biopharmaceuticals comprise glycoproteins.Therefore, differences in protein glycosylation
between humans and plants have to be taken into account and plant-speciﬁc glycosylation
has to be eliminated to avoid adverse effects on quality, safety, and efﬁcacy of the
products. The basal land plant Physcomitrella patens (moss) has been employed for the
recombinant production of high-value therapeutic target proteins (e.g., Vascular Endothelial
Growth Factor, Complement Factor H, monoclonal antibodies, Erythropoietin). Being
genetically excellently characterized and exceptionally amenable for precise gene targeting
via homologous recombination, essential steps for the optimization of moss as a bioreactor
for the production of recombinant proteins have been undertaken. Here, we discuss the
glyco-engineering approaches to avoid non-humanN- andO-glycosylation on target proteins
produced in moss bioreactors.
Keywords: Physcomitrella patens, moss bioreactor, plant-made pharmaceuticals, glycosylation, posttranslational
modifications
INTRODUCTION
Biopharmaceuticals are indispensable in modern medicine. In
2010 more than 200 biopharmaceuticals were available on the
market and around 10–20 more are approved every year (Walsh,
2010a). As the biggest group of biopharmaceuticals consists of
pharmaceutical recombinant proteins, this term is often used as
a synonym for the former. The biochemical and pharmacologi-
cal properties of a protein are not only determined by its amino
acid sequence but also largely inﬂuenced by a palette of modi-
ﬁcations that proteins undergo co- or posttranslationally (Mann
and Jensen, 2003), usually grouped together and referred to as
posttranslational modiﬁcations (PTMs). Common PTMs found
in pharmaceutical proteins are glycosylation, hydroxylation, car-
boxylation, amidation, sulfatation, disulﬁde bond formation, and
proteolytic processing (Walsh and Jefferis, 2006). Among these,
glycosylation is the most frequent PTM, being present in at least
40% of the pharmaceutical recombinant proteins available on
the market (Walsh, 2010b). The presence and quality of glyco-
sylation plays a crucial role for the pharmacological properties
of a therapeutic protein by inﬂuencing protein folding and sta-
bility, serum half-life, in vivo activity, pharmacokinetics, and
immunogenicity (Li and d’Anjou, 2009). Approximately 50% of
all eukaryotic proteins are predicted to be glycosylated and this
proportion increases substantially with respect to human serum
proteins, which are main targets as biopharmaceuticals (Apweiler
et al., 1999).
The workhorse for the production of simple proteins is
Escherichia coli, the best characterized expression system offer-
ing high product yields at low costs (Walsh, 2010a). However,
this microorganism is not able to perform some PTMs, which are
indispensable for recombinant therapeutical proteins (Kamionka,
2011). Consequently, mammalian cell lines are the preferred
expression systems for the production of recombinant glyco-
proteins, as their protein glycosylation patterns largely resemble
those of humans (Schmidt, 2004). Among the mammalian cell
lines, Chinese hamster ovary (CHO) cells comprise the leading
host system for current biopharmaceuticals, even though sev-
eral CHO-derived products presented non-human glycosylation
(Chung et al., 2008; Hossler et al., 2009; Omasa et al., 2010; Kim
et al., 2012).
As higher eukaryotes, plants are able to synthesize com-
plex multimeric proteins and perform PTMs in a simi-
lar manner as humans do. Therefore, plants and plant
cell cultures are gradually gaining acceptance as production
hosts for recombinant biopharmaceuticals. The ﬁrst plant-
made pharmaceutical (PMP) received market approval in 2012
(http://www.protalix.com/products/elelyso-taliglucerase-alfa.asp)
and several additional PMPs are being tested in clinical trials
(reviewed in Paul and Ma, 2011). The host system for ElelysoTM,
a recombinant glucocerebrosidase for the treatment of the lysoso-
mal storage disease Morbus Gaucher, is a carrot-based cell line
established by Protalix (Shaaltiel et al., 2007). It is cultured in
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bioreactors based on disposable plastic bags. While other fre-
quently used plant systems like alfalfa, tobacco, and Nicotiana
benthamiana need to be grown in greenhouses, bioreactor culti-
vation is established for the aquatic plant Lemna minor and for
the moss Physcomitrella patens (Decker and Reski, 2007; Paul and
Ma, 2011; Paul et al., 2013). Within the following sections we will
focus on the special features for biopharmaceutical production
and achievements within glyco-engineering of the moss system.
MOSS CULTIVATION AND ENGINEERING CHARACTERISTICS
The non-seed plant P. patens, a moss, is a well-established model
system for evolutionary and functional genomics approaches
(Cove et al., 2006; Menand et al., 2007; Mosquna et al., 2009;
Khraiwesh et al., 2010; Sakakibara et al., 2013). It can be grown
throughout its complete life cycle under contained conditions
in vitro in a simple mineral medium (Frank et al., 2005; Strot-
bek et al., 2013). The germination of the haploid spores leads
to the growth of protonema (Figure 1A), a branched ﬁlamen-
tous tissue which comprises two distinct cell types, chloronema
and caulonema. Every cell is in direct contact with the culture
medium, allowing efﬁcient nutrient uptake and product secretion
(Schillberg et al., 2013). This young tissue can be maintained
in suspension cultures without any addition of phytohormones,
only by mechanical disruption of the ﬁlaments. In contrast to
immortalized or de-differentiatedmammalian or higher-plant cell
cultures, which are prone to instability or somaclonal variation
(Larkin and Scowcroft, 1981; Xu et al., 2011; Bailey et al., 2012), the
fully differentiated protonema tissue is genetically stable (Reutter
and Reski, 1996). In the next developmental step, buds differ-
entiating from protonema cells give rise to the adult plant, the
leafy gametophore, consisting of shoot-like, leaf-like, and root-
like tissues (Figure 1B). After fertilization of the gametes, the
sporophyte, the only diploid tissue in the life cycle of mosses,
grows on and is sustained by the gametophore (Reski et al., 1998).
In vitro cultivation of all stages can be performed either on agar
plates or as suspension cultures in liquid media. The availabil-
ity of efﬁcient protocols for protoplast isolation (Figure 1C) and
transfection (Rother et al., 1994; Strotbek et al., 2013) and an
excellent regeneration capacity of single transfected cells to whole
plants make genetic engineering of moss a straight-forward and
frequently used approach (e.g., Lorenz et al., 2003; Qudeimat
et al., 2008; Ludwig-Müller et al., 2009; Mosquna et al., 2009;
Khraiwesh et al., 2010; Sakakibara et al., 2013). The created moss
strains can be preserved by cryo-conservation (Schulte and Reski,
2004), and thus can serve as Master Cell Banks. The International
Moss Stock Center IMSC, a reference center for moss ecotypes
and transgenic lines, provides a service for long-term storage
(http://www.moss-stock-center.org).
The employment of in vitro axenic plant cell or tissue cul-
tures offers an environment in which contamination with human
pathogens is rather unlikely (Schillberg et al., 2013). Moreover,
only in these systems culture conditions can be precisely controlled
and standardized (Hohe andReski, 2005), which is essential for the
production of pharmaceuticals according to good manufacturing
practice (GMP) guidelines (Fischer et al., 2012).
Various scales of highly controllable cultivation devices were
developed for Physcomitrella, ranging from simple shaking
ﬂasks (Figure 1D) and 5 L aerated ﬂasks to diverse forms
of photobioreactors, including stirred glass tank bioreactors
with a volume of up to 15 L (Figure 1E; Hohe and Reski,
2002) and a modular tubular bioreactor with a working vol-
ume of up to 100 L (reviewed in Decker and Reski, 2008,
2012). More recently, disposable wave-bag reactors (Figure 1F)
were employed for high-density protein production purposes
under full cGMP compliance (www.greenovation.com). Sev-
eral pharmaceutically interesting proteins have been synthesized
in moss bioreactors, among them the growth factors vascu-
lar endothelial growth factor (VEGF; Baur et al., 2005) and
erythropoietin (EPO; Weise et al., 2007) as well as the ﬁrst
marketed product for research use, human FGF7/keratinocyte
growth factor (KGF; www.greenovation.com). In addition, pro-
teins with a function in immune responses like IgGs (Schuster
et al., 2007; Kircheis et al., 2012) and the complement-regulatory
protein factor H (Büttner-Mainik et al., 2011) were produced
in moss. Furthermore, two products for enzyme-replacement
FIGURE 1 | Physcomitrella patens in vitro cultivation and schematic
representation of a knockout construct for gene targeting. (A) young
ﬁlamentous tissue, protonema, ideal for suspension cultures; (B) adult leafy
moss plant (gametophore); (C) protoplasts; (D) small scale liquid culture in
ﬂasks; (E) stirred tank bioreactor; (F) wave bioreactor (image courtesy of
greenovation Biotech GmbH); (G) illustration of allele replacement via
homologous recombination. The regions homologous to the targeted gene,
which are used for the knockout construct, are shown in gray, and the
inserted selection cassette is depicted in white. Thick lines represent
introns and rectangles exons. Scale bars 50 μm (A,B), 500 μm (C).
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therapies, human alpha-galactosidase and glucocerebrosidase
are expected to reach clinical trial phases by the end of 2014
(www.greenovation.com).
The use of Physcomitrella as a production host for recombinant
biopharmaceuticals was facilitated by well-developed molecu-
lar toolboxes. Heterologous as well as endogenous promoters
were characterized for their suitability to achieve high levels
of recombinant product (Horstmann et al., 2004; Weise et al.,
2006). In addition, several moss-derived signal peptides were
evaluated for improved secretion of the recombinant product
to the surrounding medium (Schaaf et al., 2004, 2005; Weise
et al., 2006). The moss genome sequence is available since 2008
(Rensing et al., 2008), and together with nearly 400,000 expressed
sequence tags (ESTs) obtained from different experimental condi-
tions, tissues, and developmental stages (Nishiyama et al., 2003;
Lang et al., 2008) it allows a reliable prediction of gene struc-
tures. The internet resource www.cosmoss.org provides access
to a high-quality functional annotation including more than
32,000 protein-coding genes (Zimmer et al., 2013). This resource
was very convenient for the identiﬁcation of genes involved in
the glycosylation of recombinant proteins synthesized in moss
bioreactors.
However, the main driver for moss functional genomics
approaches in general and glyco-engineering in particular was the
unique accessibility of this organism for gene targeting approaches
via homologous recombination. Displaying an exceptionally high
rate of homologous recombination in mitotic cells (Strepp et al.,
1998; Schaefer, 2001; Hohe et al., 2004; Kamisugi et al., 2006),
base-speciﬁc precise genetic engineering is feasible with high efﬁ-
ciency. Undesirable gene functions can be completely eliminated
by targeted knockout approaches. The knockout construct used
for the transfection of moss protoplasts regularly consists of 700–
1000 bp genomic DNA (homologous regions) ﬂanking each side
of a selection cassette, which interrupts or replaces the target gene
when indicated (Figure 1G). Glyco-engineering of moss was suc-
cessfully accomplished by various gene targeting approaches (see
below).
PROTEIN GLYCOSYLATION AND MOSS GLYCO-ENGINEERING
Protein glycosylation is a complex and heterogeneous modi-
ﬁcation which can be classiﬁed in two main categories, N-
and O-glycosylation. In the former, the carbohydrates are
attached to the amide group of asparagine (N) in the con-
sensus sequence N-X-S/T (where X can be any amino acid
except proline, and the third amino acid can be either ser-
ine or threonine; Mononen and Karjalainen, 1984; Gavel and
von Heijne, 1990). O-glycans, on the other hand, are attached
to the hydroxyl group of serine (S), threonine (T), hydroxyly-
sine or hydroxyproline (Hyp; Varki et al., 2009). In contrast
to N-glycosylation, consensus sequences for O-glycosylation in
mammals are notwell deﬁned or non-existing (Hansen et al., 1998;
Julenius et al., 2005).
N-glycosylation in animals is a largely cell-type and species-
speciﬁc feature (Raju et al., 2000; Croset et al., 2012). Moreover,
potential glycosylation sites on a given protein can be either
unmodiﬁed or occupied by varying glycan structures which result
from the maturation of the glycan throughout the endoplasmic
reticulum (ER) and the Golgi apparatus (GA), leading to micro-
heterogeneity of glycoproteins (Kolarich et al., 2012). Compared
to other higher eukaryotes, plants display more conserved gly-
can patterns between different species and a less diverse palette
of N-glycans (Bosch et al., 2013), fascilitating the production of
homogeneous glycoproteins.
As higher eukaryotes, plants are able to produce N-glycans of
the complex type with the core sugar structure Man3GlcNAc2
consisting of two N-acetylglucosamine and three mannose
residues that is identical to humans (Lerouge et al., 1998; Wil-
son, 2002). Up to two terminally attached GlcNAc residues
are also common between plant and bi-antennary mammalian
complex-type glycoprotein oligosaccharides (reviewed in Gomord
et al., 2010). Differing from the human structure, which dis-
plays a fucose residue 1,6-linked to the proximal GlcNAc
moiety, most plant N-glycans carry a β1,2 xylose and an
α1,3 fucose linked to the glycan core. These sugar structures
are common for all land plants analyzed so far, including
mosses as the evolutionary oldest group (Koprivova et al., 2003;
Viëtor et al., 2003). Their presence raised concerns about plant-
produced biopharmaceuticals as they were shown to induce
antibody formation in mammals (van Ree et al., 2000; Bardor
et al., 2003; Westphal et al., 2003; Bencúrová et al., 2004; Jin
et al., 2008). The consequence of an immune response against
the pharmaceutical can lead to antibody-mediated reduction
of product efﬁcacy as well as to severe clinical complications
(Schellekens, 2002).
Consequently, ﬁrst plant glyco-engineering approaches aimed
at targeting the glycosyltransferases responsible for the addition
of these two residues. Ten years ago Arabidopsis thaliana as well
as moss lines lacking β1,2 xylosylation and α1,3 fucosylation have
been generated (Koprivova et al., 2004; Strasser et al., 2004). The
predominant glycan type of the double knockout moss line for
β1,2 xylosyltransferase (XylT) and α1,3 fucosyltransferase (FucT)
was the GnGn form (GlcNAc2Man3GlcNAc2; Koprivova et al.,
2004). AXylT/FucT genotype is currently in use as genetic back-
ground formost of the recombinant products described frommoss
bioreactors.
Lacking the core fucose, the engineered moss N-glycans dif-
fer from the human ones which contain an α1,6-linked fucose
residue. However, lack of this residue proved to be advantageous
for the efﬁcacy of antibodies targeting tumor cells (Shields et al.,
2002; Shinkawa et al., 2003; Cox et al., 2006; Schuster et al., 2007).
The underlying phenomenon, antibody-dependent cellular cyto-
toxicity (ADCC), comprises receptor binding and activation of a
natural killer cell by an antigen–antibody complexon the target cell
surface resulting in lysis of the target cell. Binding and activation
of the killer cells was up to 40× more efﬁcient with a monoclonal
antibody produced in glyco-engineered, fucose-lacking moss cells
compared to the same antibody produced in CHO cells (Schuster
et al., 2007).
In addition to the GnGn N-glycan form, many plant species
display α1,4 fucose, and β1,3 galactose linked to the terminal
GlcNAc residues on one or both of the antennae (Wilson, 2001).
This trisaccharide Fucα1-4(Galβ1-3)GlcNAc is known as Lewis
A (Lea) structure. It is synthesized by β1,3 galactosyltransferases
(GalT) and α1,4 fucosyltransferases as the last steps of N-glycan
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maturation in the plant GA (reviewed in Gomord et al., 2010).
In contrast to the high prevalence of xylose and core fucose
residues on plant N-glycans, Lea structures are found in a much
lower proportion (Fitchette-Lainé et al., 1997; Koprivova et al.,
2003; Viëtor et al., 2003; Strasser et al., 2007). However, Lea
epitopes were described on recombinant proteins produced in
plants (Petruccelli et al., 2006; Weise et al., 2007; Castilho et al.,
2013). The production of recombinant human EPO (rhEPO) in
both moss and N. benthamiana, lead to proteins decorated with
high amounts of Lea structures (Weise et al., 2007; Castilho et al.,
2013). Although Lea epitopes are found in humans as part of
the Lewis-positive histo-blood groups (Henry et al., 1995), they
are rarely present in healthy adults, but increased in patients
with certain types of cancer (Zhang et al., 1994). Furthermore,
antibodies against Lea epitopes are frequent (Wilson et al., 2001).
Therefore, it is advisable to remove the respective β1,3 galactose
and α1,4 fucose residues from plant-produced recombinant
products.
A single putativeα1,4 fucosyltransferase genewas detected in the
moss genome. While the targeted knockout of this gene resulted
in the loss of terminal α1,4 fucose residues, β1,3-linked galactoses
were still present on moss N-glycans. In contrast to the single-
copy α1,4 fucosyltransferase gene, 13 putative galt homologs were
identiﬁed in P. patens. Out of these, exclusively one gene (galt1)
was shown to be responsible for the synthesis of Lea in moss. The
disruption of galt1 alone resulted in the absence of the complete
Lea epitope, not only of the galactose residue but also of the ter-
minal fucose, both in the total moss N-glycan pool and on the
moss-produced rhEPO (Parsons et al., 2012). The absence of the
α1,4 fucose in the galt1 knockout line (galt1) with intact α1,4
fucosyltransferase activity conﬁrmed that this is the last enzyme
in the plant N-glycosylation pathway and that the presence of
galactose on the substrate is indispensable for the fucosyltrans-
ferase activity (Parsons et al., 2012). The lack of GalT1 activity
did not affect the moss growth rate. The homogeneity of the
rhEPO glycosylation achieved in the moss galt1 knockout line was
remarkable, with almost only one glycosylation form, the aimed
core structure with terminal GlcNAc residues (Parsons et al., 2012;
Figure 2).
In humans, the GnGn glycan is frequently further elongated
with galactose added in β1,4 linkage and this is often capped
with sialic acid residues. The targeted insertion (“knockin”) of
the human β1,4 galt into the moss genome demonstrated the gen-
eral feasibility of β1,4 galactosylation of moss N-glycans (Huether
et al., 2005; Parsons et al., 2012). Further terminal elongation of
plantN-glycans has been demonstrated forN. benthamiana which
transiently produced glycoproteins with human-like sialylation
(Castilho et al., 2013; Jez et al., 2013). This will be a future task
for moss glyco-engineering.
Outstanding success has been achieved so far by engineering
plant N-glycosylation patterns for the production of humanized
glycoproteins. In contrast, the issue of adverse O-glycosylation
in PMPs has not been addressed in the same detail. Concern-
ing plant O-glycan engineering, recombinant proteins displaying
human so-called mucin-type O-glycosylation were generated
recently (Daskalova et al., 2010; Castilho et al., 2012; Yang et al.,
2012). In contrast to rather conserved N-glycosylation patterns,
FIGURE 2 | Glycopeptides of moss-produced rhEPO from two
glyco-engineered moss lines. Comparison of the mass spectra for the
rhEPO tryptic peptide harboring two glycosylation sites (EAENITTGCAEH-
CSLNENITVPDTK) produced in glyco-engineered moss lines: double KO
XylT/FucT and triple KO XylT/FucT/GalT (based on Parsons et al., 2012).
Salt adducts are marked with asterisks. The glycosylation patterns are
schematized with sugar symbols above each peak. Lea structures are
totally absent in the triple KO line.
plant-typical O-glycosylation differs fundamentally from the typ-
ical human mucin-type O-glycosylation (reviewed by Gomord
et al., 2010), and was shown to induce the formation of anti-
bodies (Léonard et al., 2005). In plants, the main attachment
site for O-glycosylation is 4-trans-Hyp (reviewed by Showal-
ter, 2001), while no glycosylation of Hyp occurs in animals
(Gorres and Raines, 2010). Hyp is generated posttranslation-
ally by prolyl 4-hydroxylases (P4H) via hydroxylation of proline.
Prolyl-hydroxylation is a very common modiﬁcation both in
mammals and in plants, though recognition sequences differ. In
plants, the target motif for O-glycosylation after P4H-catalyzed
hydroxylation, the so-called glycomodules present on Hyp-rich
glycoproteins (HRGPs), are deﬁned (Kieliszewski and Lamport,
1994) and validated (Tan et al., 2003; Shimizu et al., 2005).
In silico analysis of the human proteome revealed that 30%
of the human proteins bear a recognition sequence for plant
P4Hs (Gomord et al., 2010), thus being putative candidates for
non-human prolyl-hydroxylation when recombinantly produced
in plant-based systems. In fact, undesired plant-typical prolyl-
hydroxylation and in some cases even non-humanO-glycosylation
of biopharmaceuticals was reported (Karnoup, 2005; Weise et al.,
2007; Pinkhasov et al., 2011). The most direct strategy to avoid
non-human O-glycosylation in PMPs is the elimination of the
anchor Hyp, which itself is an undesired PTM performed by plant
P4H enzymes.
After systematic disruption of each of the six p4h genes in
Physcomitrella, targeted deletion of p4h1 resulted in the com-
plete elimination of the previously reported prolyl-hydroxylation
of moss-produced rhEPO (Parsons et al., 2013). As prolyl-
hydroxylation and further glycosylation of plant extracellular
matrix and cell wall proteins play important roles for growth,
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cell differentiation, and stress adaption (Lamport et al., 2006;
Velasquez et al., 2011)we expected a negative impact on the growth
rate of the lines. However, thep4h1moss lines were not impaired
neither in growth or development nor in protein productivity
(Parsons et al., 2013).
The ease of gene targeting in moss enabled glyco-engineering
approaches for the elimination of any plant-typical immunogenic
residues. This provides a plant-based system offering the stable
production of safe protein therapeutics.
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